Agricultural and Aquatic Applications of XIAP-BIR3 Conjugates

Publication ID: 24-11857609_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Agricultural and Aquatic Applications of XIAP-BIR3 Conjugates,” Published Technical Disclosure No. 24-11857609_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857609_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,609.

Summary of the Inventive Concept

The present disclosure relates to novel applications of XIAP-BIR3 conjugates in agriculture and aquaculture, enabling improved crop yields, water conservation, and disease prevention in plants and aquatic animals.

Background and Problem Solved

The original patent focused on ocular delivery of cell permeant therapeutics for treating retinal edema. However, the XIAP-BIR3 conjugate's unique properties, such as enhanced signal transmission and water retention, can be leveraged to address pressing issues in agriculture and aquaculture, including water scarcity, crop losses, and disease outbreaks.

Detailed Description of the Inventive Concept

The new inventive concept comprises systems, methods, and compositions that utilize XIAP-BIR3 conjugates to improve agricultural irrigation, crop yields, and disease prevention in plants, as well as detect and prevent water-borne diseases in aquatic animals. Specifically, the conjugate enhances signal transmission between sensors and controllers in irrigation systems, promotes water retention in soil, and facilitates the delivery of fungicides to infected plant tissue. In aquaculture, the conjugate enables the detection of water quality changes and the targeted delivery of treatments to affected aquatic animals.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the application of XIAP-BIR3 conjugates, moving from ocular therapeutics to agricultural and aquatic uses. The inventive step lies in recognizing the conjugate's potential to address specific challenges in these industries and developing novel systems, methods, and compositions that capitalize on its unique properties.

Alternative Embodiments and Variations

Alternative embodiments may include using different types of sensors, controllers, or treatment units in agricultural and aquaculture applications. Variations may involve adapting the XIAP-BIR3 conjugate for use in other industries, such as environmental monitoring or bioremediation.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agricultural and aquaculture industries, where water conservation, crop yields, and disease prevention are critical concerns. The market for XIAP-BIR3-based solutions is expected to be substantial, with potential applications in precision agriculture, sustainable aquaculture, and environmental monitoring.

CPC Classifications

SectionClassGroup
A A61 A61K38/55
A A61 A61K9/0048
A A61 A61K47/64
A A61 A61P27/02

Field of Art

Biotechnology and pharmaceutical delivery systems, with expertise in conjugate design, peptide-based drug delivery, and cross-industry applications of molecular technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in biotechnology, biochemistry, or pharmaceutical sciences, possessing knowledge of drug delivery mechanisms, conjugate technologies, and interdisciplinary applications of molecular compounds

Obviousness Rationale

A PHOSITA would recognize that the XIAP-BIR3 conjugate's core functionality of targeted molecular delivery is readily adaptable across different technical domains. The source patent's demonstration of cell-penetrating peptide conjugates for ocular delivery provides a clear template for exploring alternative application contexts. The PTD's agricultural and aquatic variations represent predictable extensions of the fundamental molecular delivery mechanism disclosed in the original patent.

Obvious Combinations & Variations

Source Patent Element
Cell-penetrating peptide conjugate (Penetratinl-XBIR3) for targeted molecular delivery to retinal tissues
PTD Variation
Using the same conjugate for signal transmission in agricultural sensor networks and targeted delivery in irrigation systems
Obviousness Reasoning
A PHOSITA would recognize that molecular signal enhancement is a predictable application of cell-penetrating conjugate technologies across different systems
Source Patent Element
Eye drop formulation containing XIAP-BIR3 conjugate for targeted therapeutic delivery
PTD Variation
Repurposing the eye drop formulation for applying treatments to agricultural crops and aquatic environments
Obviousness Reasoning
The delivery mechanism is fundamentally consistent, representing a known technique of adapting pharmaceutical formulation technologies to alternative domains
Source Patent Element
Molecular conjugate designed to enhance cellular penetration and targeted delivery
PTD Variation
Applying the conjugate to enhance fungicide delivery and water quality monitoring in agricultural and aquatic systems
Obviousness Reasoning
A PHOSITA would find it obvious to extend the molecular delivery mechanism to other targeted treatment scenarios with finite, predictable implementation strategies
Source Patent Element
Concentration ranges for molecular conjugate (0.1 μM to 1,000 μM)
PTD Variation
Utilizing similar concentration ranges for agricultural irrigation and aquaculture applications
Obviousness Reasoning
The established concentration parameters provide a direct template for adapting the conjugate to new technical domains with minimal experimental optimization
35 U.S.C. § 103 Summary: Based on US Patent 11857609's disclosure of XIAP-BIR3 conjugate delivery technologies, the present publication demonstrates that a person having ordinary skill in the art would find the agricultural and aquatic applications of said conjugate to be obvious variations. The fundamental molecular delivery mechanism, established concentration ranges, and cell-penetrating peptide technologies provide a clear technological foundation for extending the original ocular therapeutic approach to alternative technical domains, thus rendering subsequent claims of novelty invalid under 35 U.S.C. § 103.

Original Patent Information

Patent NumberUS 11,857,609
TitleOcular delivery of cell permeant therapeutics for the treatment of retinal edema
Assignee(s)The Trustees of Columbia University in the City of New York